Magnetic Resonance (MR) Spectroscopy and Diffusion Tensor Imaging in Determining Brain Injury and Subsequent Clinical Outcome in Patients of Moderate Brain Trauma

NCT ID: NCT00760903

Last Updated: 2017-01-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2003-06-30

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to use magnetic resonance spectroscopy (MRS) and diffusion tensor imaging (DTI) to assess for traumatic brain injury and determine if there is any correlation of these findings to clinical outcome. MR spectroscopy using 2D-CSI (a multi voxel technique) of the corpus callosum, basal ganglia, lobar white matter and brainstem may reveal areas of injury and quantification of the metabolites from these areas may be used to correlate with imaging findings and clinical evaluation. White matter disruption in these areas is commonly seen after TBI, caused by diffuse axonal injury. It has been implicated in the long term outcomes in these patients, but has been difficult to assess by standard radiologic studies.

By the use of DTI it may be possible to demonstrate damaged white matter tracts which could be helpful in the evaluation of traumatic brain injury. Most TBI subjects have injuries that involved torque to the brain. This results in a shearing injury to the long white matter tracts, which has been hypothesized to be related to cognitive outcome.

Also, to demonstrate that MRS and DTI prove valuable in predicting outcome in patients of moderate brain trauma by conducting progressive studies acutely (within 24 hours) and long term (4-6 weeks). Most patients will most likely be followed clinically for over a year, and, if clinical indicated, farther scanning can be done at a later date.

By comparing fraction anisotropy, ADC values, and metabolic ratios by the use of DTI and MRS in the adult and pediatric populations, may help to assess differences in recovery.

Lastly, a comparison between the two groups in changes in brain metabolism and/or white matter tract disruption/re-connection after TBI with and/or without links to outcome can be done.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to determine if MRI imaging can accurately detect the clinical outcome (extent of recovery) of patients who have moderate to severe brain injury. This study may show that MRI can provide a clearer picture on the extent of the brain injury and help medical physicians decide how to best treat these patients with a more accurate idea of the brain function of the recovering patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Trauma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

> 18 years moderate head trauma

Group I: (Pilot group): 5-10 patients \> 18 years old, gender and race indifferent with moderate head trauma.

Conventional MRI of the brain

Intervention Type OTHER

MR spectroscopy (MRS)

Intervention Type OTHER

MR Diffusion Tensor Imaging (DTI)

Intervention Type OTHER

> 18, gender and race indifferent

Group II: 30 patients \> 18 years old, gender, and race indifferent with moderate head trauma

Conventional MRI of the brain

Intervention Type OTHER

MR spectroscopy (MRS)

Intervention Type OTHER

MR Diffusion Tensor Imaging (DTI)

Intervention Type OTHER

Pediatric

Group III: 30 patients \< 18 years old, gender and race indifferent with moderate head trauma (pediatric patient group)

Conventional MRI of the brain

Intervention Type OTHER

MR spectroscopy (MRS)

Intervention Type OTHER

MR Diffusion Tensor Imaging (DTI)

Intervention Type OTHER

Pre-evaluated

Group IV: 10-20 patients age, gender and race indifferent with moderate head trauma that have been examined with conventional MRI of the brain, MRS and DTI as clinically requested. The images of these patients will be evaluated retrospectively for data- point collection.

Conventional MRI of the brain

Intervention Type OTHER

MR spectroscopy (MRS)

Intervention Type OTHER

MR Diffusion Tensor Imaging (DTI)

Intervention Type OTHER

Control Group

Group V (control group): 20 volunteers without prior history of traumatic brain injury or neurological problems.

Conventional MRI of the brain

Intervention Type OTHER

MR spectroscopy (MRS)

Intervention Type OTHER

MR Diffusion Tensor Imaging (DTI)

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Conventional MRI of the brain

Intervention Type OTHER

MR spectroscopy (MRS)

Intervention Type OTHER

MR Diffusion Tensor Imaging (DTI)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of acute moderate brain trauma

Exclusion Criteria

* Patients who are medically unstable or have CT findings that may interfere with the study such as:

* a large hemorrhage or edema
* encephalomalacia
* prior neurosurgeries
* hardware placed in the head or neck
* prior head trauma
* history of neurological conditions
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Michigan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pia C Maly Sundgren, MD, PhD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Michigan

Ann Arbor, Michigan, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2003-0053

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

High-field Brain Magnetic Resonance Spectroscopy
NCT02053701 ACTIVE_NOT_RECRUITING